The DOI matches its Crossref record; 33 of the 35 references it cites were found in a registry or an index.
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
Open accessAbstract
Background Sickle cell anaemia (SCA) is associated with significant morbidity from acute complications and organ dysfunction beginning in the first year of life. In the first multicenter randomised double-blinded trial in very young children with SCA, the impact of hydroxyurea (hydroxycarbamide) therapy on organ dysfunction, clinical complications, and laboratory findings, and its toxicity, were examined. Methods Eligible subjects had HbSS or Sβ0thalassaemia, were age 9–18 months at randomisation, and were not selected for clinical severity. Subjects received liquid hydroxyurea, 20 mg/kg/day, or placebo for two years. Primary study endpoints were splenic function (qualitative uptake on 99Tc spleen scan) and renal function (glomerular filtration rate by 99mTc-DTPA clearance). Additional evaluations included: blood counts, HbF, chemistry profiles, spleen function biomarkers, urine osmolality, neurodevelopment, transcranial Doppler ultrasonography, growth, and mutagenicity. Study visits occurred every two to four weeks. Findings Ninety-six subjects received hydroxyurea and 97 placebo; 86% completed the study. Significant differences were not seen for the primary endpoints, but suggestive benefit was noted in quantitative measures of spleen function. Hydroxyurea significantly decreased pain and dactylitis with trends for decreased acute chest syndrome, hospitalisation and transfusion. Hydroxyurea increased haemoglobin and HbF and decreased WBC count. Toxicity was limited to mild-moderate neutropaenia. Interpretation Although hydroxyurea treatment did not reduce splenic and renal dysfunction assessed by primary endpoint measures, it resulted in major clinical benefit because of diminished acute complications, favorable haematologic results, and a lack of unexpected toxicities. Based on the safety and efficacy data from this trial, hydroxyurea can now be considered for all very young children with SCA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, all children seem to have a robust HbF response to hydroxyurea that retards the natural age-related fall in HbF.87”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [87]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340
Pain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Prediction of Adverse Outcomes in Children with Sickle Cell Disease
Miller, S. T., Sleeper, L. A., Pegelow, C. H., Enos, L. E., Wang, W. C., Weiner, S. J., Wethers, D. L., Smith, J., & Kinney, T. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200001133420203 · Cited by 508
Self-citationThe risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up
Steinberg, M. H., McCarthy, W. F., Castro, O., Ballas, S. K., Armstrong, F. D., Smith, W., Ataga, K., Swerdlow, P., Kutlar, A., DeCastro, L., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21699 · Cited by 486
Self-citationVoskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
How I use hydroxyurea to treat young patients with sickle cell anemia
Ware, R. E. (2010) · Blood · doi:10.1182/blood-2009-04-146852 · Cited by 406
Self-citationZimmerman, S. A., Schultz, W. H., Davis, J. S., Pickens, C. V., Mortier, N. A., Howard, T. A., & Ware, R. E. (2003) · Blood · doi:10.1182/blood-2003-07-2475 · Cited by 312
Self-citationSystematic Review: Hydroxyurea for the Treatment of Adults with Sickle Cell Disease
Lanzkron, S., Strouse, J. J., Wilson, R. F., Beach, M. C., Haywood, C., Park, H., Witkop, C., Bass, E. B., & Segal, J. B. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-12-200806170-00221 · Cited by 288
Cited by
Sorted by citations
Items 201–300 of 796
Hoppe, C. C., & Neumayr, L. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.01.014 · Cited by 38
Kutlar, A., Reid, M. E., Inati, A. C., Taher, A. T., Abboud, M. R., El-Beshlawy, A. M., Buchanan, G. R., Smith, H. P., Ataga, K. I., Perrine, S. P., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23533 · Cited by 35
Self-citationPernell, B. M., DeBaun, M. R., BECKER, K. L., Rodeghier, M., Bryant, V., & Cronin, R. M. (2017) · Applied Clinical Informatics · doi:10.4338/aci-2016-12-ra-0203 · Cited by 33
Colombatti, R., Palazzi, G., Masera, N., Notarangelo, L. D., Bonetti, E., Samperi, P., Barone, A., Perrotta, S., Facchini, E., Miano, M., et al. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26774 · Cited by 35
Su, Z. T., Segal, J. B., Lanzkron, S., & Ogunsile, F. J. (2019) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4860 · Cited by 35
Barriers to the use of hydroxyurea in the management of sickle cell disease in Nigeria
Adeyemo, T. A., Diaku-Akinwumi, I., Ojewunmi, O. O., Bolarinwa, A. B., & Adekile, A. D. (2019) · Hemoglobin · doi:10.1080/03630269.2019.1649278 · Cited by 35
Carden, M. A., Fasano, R. M., & Meier, E. R. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100637 · Cited by 38
Aneni, E. C., Hamer, D. H., & Gill, C. J. (2013) · Tropical Medicine & International Health · doi:10.1111/tmi.12056 · Cited by 34
Interventions for preventing silent cerebral infarcts in people with sickle cell disease
Estcourt, L. J., Fortin, P. M., Hopewell, S., Trivella, M., Doree, C. J., & Abboud, M. R. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012389.pub2 · Cited by 35
Sickle cell disease in children: an update of the evidence in low- and middle-income settings
Odame, I. (2022) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-323633 · Cited by 36
A phase 1/2 trial of HQK‐1001, an oral fetal globin inducer, in sickle cell disease
Kutlar, A., Ataga, K. I., Reid, M. E., Vichinsky, E. P., Neumayr, L., Blair‐Britt, L., Labotka, R., Glass, J., Keefer, J. R., Wargin, W. A., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23306 · Cited by 34
Self-citationEmerging pharmacotherapeutic approaches for the management of sickle cell disease
Torres, L. S., & Conran, N. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1548610 · Cited by 35
Okam, M. M., Esrick, E. B., Mandell, E., Campigotto, F., Neuberg, D. S., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-635391 · Cited by 34
A systematic review of the literature for severity predictors in children with sickle cell anemia
Meier, E. R., Fasano, R. M., & Levett, P. (2017) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2017.01.014 · Cited by 33
Özdoğu, H., Boğa, C., Yeral, M., Kozanoğlu, İ., Gereklioğlu, Ç., Aytan, P., Kasar, M., Asma, S., Büyükkurt, N., Solmaz, S., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0111-y · Cited by 33
Current perspectives of sickle cell disease in Nigeria: changing the narratives
Ojewunmi, O. O., Adeyemo, T. A., Ayinde, O. C., Iwalokun, B. A., & Adekile, A. D. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1631155 · Cited by 32
Ware, R. E., & Dertinger, S. D. (2021) · British Journal of Haematology · doi:10.1111/bjh.17323 · Cited by 34
Self-citationEvans, C., Orf, K., Horvath, E., Levin, M., Fuente, J. D. L., Chakravorty, S., & Cunnington, A. J. (2015) · Haematologica · doi:10.3324/haematol.2015.128777 · Cited by 33
Improved Splenic Function After Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Nickel, R. S., Seashore, E. L., Lane, P. A., Alazraki, A. L., Horan, J., Bhatia, M., & Haight, A. E. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.25904 · Cited by 33
Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program
Nottage, K. A., Hankins, J. S., Smeltzer, M. P., Mzayek, F., Wang, W. C., Aygün, B., & Gurney, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072077 · Cited by 32
Self-citationThe trials and hopes for drug development in sickle cell disease
Ataga, K. I., & Stocker, J. W. (2015) · British Journal of Haematology · doi:10.1111/bjh.13548 · Cited by 32
Ofakunrin, A. O. D., Okpe, E. S., Afolaranmi, T., Olaosebikan, R., Kanhu, P. U., Adekola, K., Dami, N., & Sagay, A. S. (2021) · African Health Sciences · doi:10.4314/ahs.v21i2.36 · Cited by 32
Hydroxyurea treatment of children with hemoglobin SC disease
Yates, A. M., Dedeken, L., Smeltzer, M. P., Lebensburger, J. D., Wang, W. C., & Robitaille, N. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24283 · Cited by 32
Self-citationPhytomedicines (medicines derived from plants) for sickle cell disease
Oniyangi, O., & Cohall, D. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004448.pub5 · Cited by 32
Teixeira, R., Terse-Ramos, R., Ferreira, T. A., Machado, V. R., Perdiz, M. I., Lyra, I. M., Nascimento, V. M. L., Boa‐Sorte, N., Andrade, B. B., & Ladeia, A. M. T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184076 · Cited by 31
Casella, J. F., Adams, R. J., Brambilla, D. J., Strouse, J. J., Maier, P., Dlugash, R., Avadhani, R., Vermillion, K. K., Tonascia, J., Voeks, J. H., et al. (2018) · Clinical Trials · doi:10.1177/1740774518807160 · Cited by 31
Self-citationSickle cell disease in Germany: Results from a national registry
Kunz, J. B., Lobitz, S., Grosse, R., Oevermann, L., Hakimeh, D., Jarisch, A., Cario, H., Beier, R., Schenk, D., Schneider, D. T., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28130 · Cited by 31
Risk factor analysis of cerebral white matter hyperintensities in children with sickle cell disease
van der Land, V., Mutsaerts, H. J. M. M., Engelen, M., Heijboer, H., Roest, M., Hollestelle, M. J., Kuijpers, T. W., Nederkoorn, P. J., Cnossen, M. H., Majoie, C. B. L. M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13819 · Cited by 30
George, P. E., Bazo‐Alvarez, J. C., & Sheehan, V. (2018) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001177 · Cited by 30
Adamkiewicz, T. V., Yee, M. E. M., Thomas, S., Tunali, A., Lai, K., Omole, F. S., Lane, P. A., & Yildirim, I. B. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009643 · Cited by 31
Njoku, F. U., Pugh, N. L., Brambilla, D. J., Kroner, B. L., Shah, N., Treadwell, M. J., Gibson, R. W., Hsu, L. L.-Y., Gordeuk, V. R., Glassberg, J., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27279 · Cited by 30
Self-citationEthical Challenges in Hematopoietic Cell Transplantation for Sickle Cell Disease
Nickel, R. S., & Kamani, N. R. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.08.034 · Cited by 31
Takahashi, T., Okubo, Y., & Handa, A. (2017) · Pediatric Blood & Cancer · doi:10.1002/pbc.26885 · Cited by 30
Hydroxyurea use in young infants with sickle cell disease
Schuchard, S. B., Lissick, J., Nickel, A. J., WATSON, D. A., Moquist, K. L., Blaylark, R. M., & Nelson, S. C. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27650 · Cited by 29
McCavit, T. L. (2012) · Pediatrics in Review · doi:10.1542/pir.33.5.195 · Cited by 30
Glomerular hyperfiltration: part 2—clinical significance in children
Adebayo, O. C., Nkoy, A. B., van den Heuvel, L. P., Labarque, V., Levtchenko, E. N., Delanaye, P., & Pottel, H. (2022) · Pediatric Nephrology · doi:10.1007/s00467-022-05826-5 · Cited by 30
Mortality of New York children with sickle cell disease identified through newborn screening
Wang, Y., Liu, G., Caggana, M., Kennedy, J., Zimmerman, R., Oyeku, S. O., Werner, E. M., Grant, A. M., Green, N., & Grosse, S. D. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.123 · Cited by 30
Meremikwu, M. M., & Okomo, U. (2003) · Europe PMC (PubMed Central) · Cited by 30
Sickle cell disease: a comprehensive program of care from birth
de Montalembert, M., Tshilolo, L. M., & Allali, S. (2019) · Hematology · doi:10.1182/hematology.2019000053 · Cited by 29
Khargekar, N. C., Banerjee, A., Athalye, S., Mahajan, N., Kargutkar, N., Tapase, P., & Madkaikar, M. R. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02461-z · Cited by 32
Clinical Features of β-Thalassemia and Sickle Cell Disease
McGann, P. T., Nero, A. C., & Ware, R. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_1 · Cited by 29
Self-citationSetty, Y. B. N., Betal, S. G., Miller, R. E., Brown, D. S., Meier, M., Cahill, M., Lerner, N. B., Apollonsky, N., & Stuart, M. J. (2019) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2019.05.004 · Cited by 30
Health Supervision for Children and Adolescents With Sickle Cell Disease: Clinical Report
Yates, A. M., Aygün, B., Nuss, R., Rogers, Z. R., Hematology/Oncology, S. O., Wetmore, C., Dickens, D., Majumdar, S., Stoffman, J. M., Warwick, A. B., et al. (2024) · PEDIATRICS · doi:10.1542/peds.2024-066842 · Cited by 30
Self-citationAcute chest syndrome of sickle cell disease: genetics, risk factors, prognosis, and management
Klings, E. S., & Steinberg, M. H. (2022) · Expert Review of Hematology · doi:10.1080/17474086.2022.2041410 · Cited by 29
Lebensburger, J. D., Howard, T. A., Hu, Y., Pestina, T. I., Gao, G., Johnson, M. D., Zakharenko, S. S., Ware, R. E., TUOMANEN, E. I., Persons, D. A., et al. (2011) · Blood · doi:10.1182/blood-2011-08-374447 · Cited by 28
Self-citationSilva, I. V., Reis, A. F., Palaré, M. J., Ferrão, A., Rodrigues, T., & Morais, A. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12411 · Cited by 28
Hydroxyurea: a new old therapy for Langerhans cell histiocytosis
Zinn, D. J., Grimes, A. B., Lin, H., Eckstein, O. S., Allen, C. E., & McClain, K. L. (2016) · Blood · doi:10.1182/blood-2016-06-721993 · Cited by 28
Severe anemia early in life as a risk factor for sickle-cell kidney disease
Aban, I., Baddam, S., Hilliard, L., Howard, T. H., Feig, D. I., & Lebensburger, J. D. (2016) · Blood · doi:10.1182/blood-2016-09-738104 · Cited by 28
Self-citationZahr, R. S., Yee, M. E. M., Weaver, J., Twombley, K. E., Matar, R. N. B., Avilés, D., Sreedharan, R., Rheault, M. N., Malatesta-Muncher, R., Stone, H. K., et al. (2019) · Pediatric Nephrology · doi:10.1007/s00467-019-04237-3 · Cited by 28
Association of Hospital and Provider Types on Sickle Cell Disease Outcomes
Jan, S., Slap, G. B., Smith‐Whitley, K., Dai, D., Keren, R., & Rubin, D. M. (2013) · PEDIATRICS · doi:10.1542/peds.2013-0089 · Cited by 27
Estepp, J. H., Melloni, C., Thornburg, C. D., Wiczling, P., Rogers, Z. R., Rothman, J., Green, N., Liem, R. I., Brandow, A. M., Crary, S. E., et al. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.598 · Cited by 27
Self-citationFuture directions of sickle cell disease research: The NIH perspective
Hoots, W. K., & Shurin, S. B. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24180 · Cited by 27
Brousse, V. A. M., Arnaud, C., Lesprit, E., Quinet, B., Odièvre, M., Etienne‐Julan, M., Guillaumat, C., Elana, G., Belloy, M., Garnier, N., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101594 · Cited by 29
Hankins, J. S., Shah, N., DiMartino, L., Brambilla, D. J., Fernández, M. E., Gibson, R. W., Gordeuk, V. R., Lottenberg, R., Kutlar, A., Melvin, C. L., et al. (2020) · JMIR Research Protocols · doi:10.2196/16319 · Cited by 27
Self-citationDexter, D., & McGann, P. T. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2792 · Cited by 29
Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives
Light, J., Boucher, M., Baskin‐Miller, J., & Winstead, M. (2023) · Journal of Blood Medicine · doi:10.2147/jbm.s383472 · Cited by 27
Pulmonary Complications of Sickle Cell Disease
Khoury, R. A., Musallam, K. M., Mroueh, S. M., & Abboud, M. R. (2011) · Hemoglobin · doi:10.3109/03630269.2011.621149 · Cited by 27
Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective
Sharef, S. W., Al‐Hajri, M., Beshlawi, I., Al‐Shahrabally, A., Elshinawy, M., Zachariah, M., Tony, S., Bashir, W., Rawas, A. A., Taqi, A., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12103 · Cited by 27
Abdullahi, S. U., DeBaun, M. R., Jordan, L. C., Rodeghier, M., & Galadanci, N. A. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.01.008 · Cited by 27
Brousse, V., El Hoss, S., Bouazza, N., Arnaud, C., Bernaudin, F., Pellegrino, B., Guitton, C., Odièvre‐Montanié, M., Mames, D., Brouzes, C., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25260 · Cited by 25
Zheng, Y., Gossett, J. M., Chen, P., Barton, M., Ryan, M., Yu, J., Kang, G., Hankins, J. S., & Chou, S. T. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008647 · Cited by 26
Desai, R. J., Mahesri, M., GLOBE, D. R., Mutebi, A., Bohn, R. L., Achebe, M., Levin, R., & Schneeweiß, S. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04233-w · Cited by 26
Effects of hydroxyurea on brain function in children with sickle cell anemia
Wang, W. C., Zou, P., Hwang, S. N., Kang, G., Ding, J., Heitzer, A. M., Schreiber, J. E., Helton, K. J., & Hankins, J. S. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29254 · Cited by 26
Self-citationHeeney, M. M., Abboud, M. R., Githanga, J. N., Inusa, B. P. D., Kanter, J., Michelson, A. D., Nduba, V., Musiime, V., Apte, M., Inati, A. C., et al. (2022) · Blood · doi:10.1182/blood.2021014095 · Cited by 26
Boosalis, M. S., Sangerman, J., White, G. L., Wolf, R. F., Shen, L., Dai, Y., White, E., Makala, L., Li, Y., Pace, B. S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144660 · Cited by 26
Treatment preference and recruitment to pediatric RCTs: A systematic review
Beasant, L., Brigden, A., Parslow, R. M., Apperley, H., Keep, T., Northam, A., Wray, C., King, H., Langdon, R., Mills, N., et al. (2019) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2019.100335 · Cited by 25
Interventions for chronic kidney disease in people with sickle cell disease
Roy, N. B. A., Fortin, P. M., Bull, K. R., Doree, C. J., Trivella, M., Hopewell, S., & Estcourt, L. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012380.pub2 · Cited by 25
FOETAL HAEMOGLOBIN AND DISEASE SEVERITY IN NIGERIAN CHILDREN WITH SICKLE CELL ANAEMIA.
Adeodu, O. O., Akinlosotu, M. A., Adegoke, S. A., & Oseni, S. B. A. (2017) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2017.063 · Cited by 25
GeethaKumari, K., Kusuma, Y. S., & Babu, B. V. (2020) · The International Journal of Health Planning and Management · doi:10.1002/hpm.3081 · Cited by 25
Chronic organ injuries in children with sickle cell disease
Allali, S., Taylor, M., Brice, J., & de Montalembert, M. (2021) · Haematologica · doi:10.3324/haematol.2020.271353 · Cited by 25
Research in Sickle Cell Disease: From Bedside to Bench to Bedside
Cisneros, G. S., & Thein, S. L. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000584 · Cited by 25
Marchese, V. G., Rock, K., Harpold, A., Salazar, A., Williams, M. L., & Shipper, A. G. (2021) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/j.apmr.2021.08.022 · Cited by 25
Ferraresi, M., Panzieri, D. L., Leoni, S., Cappellini, M. D., Kattamis, A., & Motta, I. (2023) · European Journal of Pediatrics · doi:10.1007/s00431-023-04900-w · Cited by 31
Baker, C., Grant, A. M., George, M. G., Grosse, S. D., & Adamkiewicz, T. V. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25655 · Cited by 25
State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease
Puri, L., Nottage, K. A., Hankins, J. S., & Anghelescu, D. L. (2017) · Pediatric Drugs · doi:10.1007/s40272-017-0263-z · Cited by 28
Pace, B. S., Liu, L., Li, Y., & Makala, L. (2015) · Experimental Biology and Medicine · doi:10.1177/1535370215596859 · Cited by 25
Daak, A. A., Ghebremeskel, K., Mariniello, K., Attallah, B., Clough, P., & Elbashir, M. I. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2013.09.006 · Cited by 25
Meier, E. R., Byrnes, C., Lee, Y. T., Wright, E. C., Schechter, A. N., Luban, N. L. C., & Miller, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070794 · Cited by 25
Emerging drugs for sickle cell anemia
Singh, P. C., & Ballas, S. K. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.985587 · Cited by 24
Systematic review of interventional sickle cell trials registered in ClinicalTrials.gov
Lebensburger, J. D., Hilliard, L., Pair, L. E., Oster, R. A., Howard, T. H., & Cutter, G. (2015) · Clinical Trials · doi:10.1177/1740774515590811 · Cited by 24
Self-citationAnyanwu, J. N., Williams, O., Sautter, C., Kasirye, P., Hume, H. A., Opoka, R. O., Latham, T., Ndugwa, C. M., Ware, R. E., & John, C. C. (2016) · JMIR Research Protocols · doi:10.2196/resprot.5599 · Cited by 27
Self-citationCreary, S. E., Chisolm, D. J., Stanek, J. R., Hankins, J. S., & O’Brien, S. H. (2019) · JMIR mhealth and uhealth · doi:10.2196/13452 · Cited by 24
Rankine‐Mullings, A., Reid, M. E., Soares, D., Taylor‐Bryan, C., Wisdom‐Phipps, M., Aldred, K., Latham, T., Schultz, W. H., Knight‐Madden, J., Badaloo, A. V., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17698 · Cited by 24
Self-citationTrends in blood transfusion among hospitalized children with sickle cell disease
Raphael, J. L., Oyeku, S. O., Kowalkowski, M. A., Mueller, B. U., & Ellison, A. M. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24630 · Cited by 24
Sickle cell disease pain management and the medical home
Raphael, J. L., & Oyeku, S. O. (2013) · Hematology · doi:10.1182/asheducation-2013.1.433 · Cited by 24
Kassim, A. A., & DeBaun, M. R. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.868435 · Cited by 24
Dai, Y., Sangerman, J., Luo, H., Fucharoen, S., Chui, D. H. K., Faller, D. V., & Perrine, S. P. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.10.004 · Cited by 24
Elective cholecystectomy reduces morbidity of cholelithiasis in pediatric sickle cell disease
Goodwin, E. F., Partain, P. I., Lebensburger, J. D., Fineberg, N. S., & Howard, T. H. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26179 · Cited by 24
Self-citationCannas, G., Poutrel, S., & Thomas, X. (2017) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2017.015 · Cited by 24
Treating sickle cell anemia: A new era dawns
Steinberg, M. H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25724 · Cited by 25
Xanthine Oxidase Drives Hemolysis and Vascular Malfunction in Sickle Cell Disease
Schmidt, H. M., Wood, K. C., Lewis, S. E., Hahn, S. A., Williams, X. M., McMahon, B., Baust, J., Yuan, S. S., Bachman, T. N., Wang, Y., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.315081 · Cited by 24
Hydroxycarbamide: Clinical aspects
Ware, R. E. (2012) · Comptes Rendus Biologies · doi:10.1016/j.crvi.2012.09.006 · Cited by 24
Self-citationPavitra, E., Acharya, R. K., Gupta, V. K., Verma, H. K., Kang, H., Lee, J., Sahu, T. A., Bhaskar, L. V., Raju, G. S. R., & Huh, Y. S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116849 · Cited by 24
Fitzhugh, C. D., & Walters, M. C. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007708 · Cited by 23
Fogarty, H., Gaul, A., Syed, S., Aleksejenko, N., Geoghegan, R., Conroy, H., Crampton, E., Ngwenya, N., Tuohy, E., & McMahon, C. (2021) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02588-1 · Cited by 26
Aygün, B., Lane, A., Smart, L. R., Santos, B., Tshilolo, L. M., Williams, T. N., Olupot‐Olupot, P., Stuber, S. E., TOMLINSON, G. A., Latham, T., et al. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00078-4 · Cited by 28
Self-citationRigano, P., Pecoraro, A., Calvaruso, G., Steinberg, M. H., Iannello, S., & Maggio, A. (2013) · American Journal of Hematology · doi:10.1002/ajh.23531 · Cited by 23
Allogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia
Bernaudin, F., Pondarré, C., Galambrun, C., & Thuret, I. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_4 · Cited by 26
Reactivation of Fetal Hemoglobin for Treating β-Thalassemia and Sickle Cell Disease
Cui, S., & Engel, J. D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_7 · Cited by 25
Sarri, G., Bhor, M., Abògúnr̀in, Ṣ., Farmer, C., Nandal, S., Halloway, R., & Revicki, D. A. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-0930-y · Cited by 23
Metadata
- Authors
- Wang, W. C., Ware, R. E., Miller, S. T., Iyer, R. V., Casella, J. F., Minniti, C. P., Rana, S., Thornburg, C. D., Rogers, Z. R., Kalpatthi, R. V., Barredo, J. C., Brown, R. C., Sarnaik, S. A., Howard, T. H., Wynn, L. W., Kutlar, A., Armstrong, F. D., Files, B. A., Goldsmith, J. C., Waclawiw, M. A., Huang, X., & Thompson, B. W.
- Affiliations
- St. Jude Children's Research Hospital (US)
- SUNY Downstate Health Sciences University (US)
- University of Mississippi Medical Center (US)
- Johns Hopkins University (US)
- Children's National (US)
- Howard University (US)
- Duke Medical Center (US)
- The University of Texas Southwestern Medical Center (US)
- Medical University of South Carolina (US)
- University of Miami (US)
- Children's Hospital of Michigan (US)
- University of Alabama at Birmingham (US)
- Augusta University (US)
- Emory University (US)
- National Heart, Lung, and Blood Institute (US)
- Clinical Trials and Surveys Corporation (US)
- Corresponding author
- Wang, Winfred C
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2011-05
- Volume
- 377
- Issue
- 9778
- Pages
- 1663-1672
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC3133619
- OpenAlex
- W2170086069
- Semantic Scholar
- 007f7341f1586c3f34ecd96fa415bd95116f1c85
- Cited by
- 803
- References
- 35
- Citations by year
- 2026: 46 · 2025: 42 · 2024: 57 · 2023: 49 · 2022: 58 · 2021: 54 · 2020: 58 · 2019: 67 · 2018: 50 · 2017: 64 · 2016: 52 · 2015: 61 · 2014: 50 · 2013: 45 · 2012: 25
- FWCI
- 21.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (n01hb07156-19-0-1, n01hb07159-25-0-1, n01hb07153-18-0-1, n01hb07155-16-0-0, n01hb07158-17-0-0, n01hb07157-15-0-0, n01hb07152-18-0-0, n01hb07151-17-0-0, n01hb07150-20-0-1, n01hb07160-38-0-1, n01hb07154-21-0-0)
- National Heart, Lung, and Blood Institute (N01-HB-07154, N01-HB-07157, N01-HB-07160, N01 HB007155, N01-HB07155, N01-HB-07152, N01-HB-07153, N01 HB007150, N01-HB-07151, N01-HB-07158, N01-HB-07150, N01 HB007160, N01-HB-07159, N01-HB-07156)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Keywords
- hydroxyurea, sickle cell disease, infants, spleen function, renal function, acute chest syndrome, pain episodes, fetal hemoglobin, brain development, mutagenicity, drug toxicity, beta-thalassemia, organ dysfunction, growth, transcranial Doppler, glomerular filtration rate, urine osmolality
- MeSH terms
- Anemia, Sickle Cell, Antisickling Agents, Blood Cell Count, Child Development, Female, Glomerular Filtration Rate, Hemoglobins, Humans, Hydroxyurea, Infant, Male, Osmolar Concentration, Pain, Spleen, United States, Urine, Biomarkers, Technetium Tc 99m Pentetate, Treatment Outcome, Ultrasonography, Doppler, Transcranial, Acute Chest Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
